# Summary table reporting evidence of Test-retest reliability for OMERACT Filter 2.3

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Study Reference**  (Author, Year) | **Study description** | | | **Results** | | | | | **Judgement** |
| **Brief characteristics of sample\*** | | **Characteristics of testing situation** | **Interpretation of authors of adequacy**  **(+, +/-, -)** | **Scores at baseline and retest** | **Statistic used** | **Results** | **Minimal detectable change (95%CI)**  *SEM=SDbaseline x Ö (1-ICC)*  *MDC=1.96 x SEM x Ö2* | **Interpretation of authors of adequacy**  **(+, +/-, -)** |
| ***EXAMPLE:*** | | | | | | | | | |
| *adapted from Leung 2021)*  *Tillett 2020* | *Consecutive patients wth PsA fulfilled CASPAR, recruited for validation of composite measures* | * *1 week apart* * *Assumed no change in condition*   *1* | | * *140 patients recruited, 31 for test-retest reliability* * *Mean age 54 (11) years*   *Duration of PsA 5.7 (4.7) years* | *Mean (SD)*  *T1: 0.49 (0.59)*  *T2: 0.50 (0.65)*  *Mean difference=-0.004 (SD=0.28),*  *p=0.96*  *95% CI:*  *-0.114 to 0.105* | *ICC (2,1)*  *Spearman’s rho (r)* | *ICC (2,1)=0.94*  *(95% CI: 0.88-0.97)*  *r=0.93 (p<0.01)* | *SEM=0.59 x Ö (1-0.94)*  *=0.14*  *MDC=1.96 x 0.14 x Ö2*  *= 0.39* | *(+)*  *Good ICC and correlation between scores that changes were not expected. Bland/ Altman plot provided supportive evidence.* |
|  |  |  | |  |  |  |  |  |  |
|  |  |  | |  |  |  |  |  |  |
|  |  |  | |  |  |  |  |  |  |
|  |  |  | |  |  |  |  |  |  |
|  |  |  | |  |  |  |  |  |  |
|  |  |  | |  |  |  |  |  |  |
|  |  |  | |  |  |  |  |  |  |

*\*Greater detail on study design & methods can be provided in the table, ‘Description of studies in general’*

\*add more rows as necessary

***References contributing to the reporting of this table:***Kottner J, Audigé L, Brorson S, Donner A, Gajeweski BJ, Hróbjartsson A, Robersts C, Shoukri M, Streiner DL. Guidelines for reporting reliability and agreement studies (GRRAS) were proposed. J Clin Epidemiol. 2011;64(1):96-106

Valderas JM, Ferrer M, Mendívil J, Garin O, Rajmil L, Herdman M, Alonso J; Scientific Committee on "Patient-Reported Outcomes" of the IRYSS Network..Development of EMPRO: a tool for the standardized assessment of patient-reported outcome measures. Value Health. 2008 Jul-Aug;11(4):700-8. doi: 10.1111/j.1524-4733.2007.00309.x. Epub 2008 Jan 8.

Scientific Advisory Committee, Medical Outcomes Trust. Assessing health status and quality-of-life instruments: attributes and review criteria. Qual Life Res. 2002, 11:193–205. doi: 10.1023/A:1015291021312. [PubMed: 12074258]

(Example adapted from: Leung et al. HAQ-DI and the SF-36 Physical Functioning subscale provisionally endorsed as outcome measurement instruments of the physical function domain in psoriatic arthritis using OMERACT Filter 2.1 methodology. 2021 Seminars in Arthritis and Rheumatism)